UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 15, 2017
NEOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-37508 | | 27-0395455 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
2940 N. Highway 360, Grand Prairie, TX | | 75050 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (972) 408-1300
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 15, 2017. As of April 26, 2017, the record date for the Annual Meeting, there were 22,560,635 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April 28, 2017: (i) to elect Vipin Garg and Greg Robitaille as Class II directors of the Company to each serve for a three-year term expiring at the Company’s annual meeting of stockholders in 2020 and until their successors have been elected and qualified (“Proposal 1”) and (ii) to ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017 (“Proposal 2”).
The Company’s stockholders elected each of the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class II directors as follows:
Class II Director Nominee | | For | | Withhold | | Broker Non-Votes | |
Vipin Garg | | 11,385,060 | | 1,075,191 | | 7,337,403 | |
Greg Robitaille | | 11,507,297 | | 952,954 | | 7,337,403 | |
The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
For | | Against | | Abstain | |
19,568,615 | | 192,804 | | 36,235 | |
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
* * *
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 16, 2017 | NEOS THERAPEUTICS, INC. |
| |
| By: | /s/ Vipin Garg |
| | Vipin Garg |
| | President and Chief Executive Officer |
3
